share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  2024/09/17 05:32

Moomoo AI 已提取核心信息

ZyVersa Therapeutics has entered into a Sales Agreement with A.G.P./Alliance Global Partners on September 16, 2024, establishing an at-the-market (ATM) offering program with an aggregate offering price of up to $1,397,396. Under the agreement, A.G.P. will serve as the sales agent and receive a 3% commission on gross proceeds from share sales.The shares will be sold at prevailing market prices through methods permitted under Rule 415(a)(4) of the Securities Act. The offering is being conducted pursuant to the Company's effective S-3 shelf registration statement filed with the SEC. While there is no minimum offering amount required, the agreement will automatically terminate upon reaching the maximum offering amount.The Company plans to use the net proceeds for working capital and general corporate purposes, including administrative and research and development expenses. The agreement includes standard termination provisions and allows either party to suspend or terminate the offering under specified conditions.
ZyVersa Therapeutics has entered into a Sales Agreement with A.G.P./Alliance Global Partners on September 16, 2024, establishing an at-the-market (ATM) offering program with an aggregate offering price of up to $1,397,396. Under the agreement, A.G.P. will serve as the sales agent and receive a 3% commission on gross proceeds from share sales.The shares will be sold at prevailing market prices through methods permitted under Rule 415(a)(4) of the Securities Act. The offering is being conducted pursuant to the Company's effective S-3 shelf registration statement filed with the SEC. While there is no minimum offering amount required, the agreement will automatically terminate upon reaching the maximum offering amount.The Company plans to use the net proceeds for working capital and general corporate purposes, including administrative and research and development expenses. The agreement includes standard termination provisions and allows either party to suspend or terminate the offering under specified conditions.
ZyVersa Therapeutics于2024年9月16日与A.G.P./Alliance Global Partners签署销售协议，建立一个高达1,397,396美元的市场出售（ATM）提供计划。根据协议，A.G.P.将担任销售代理，并获得出售股票毛收入的3%佣金。股票将在允许的市场价格下通过证劵法第415(a)(4)条款的协议方法出售。该发行是根据公司提交给美国证券交易委员会的有效S-3架构注册声明进行的。虽然没有最低发行金额的要求，但一旦达到最大发行金额，协议将自动终止。公司计划将净收益用于营运资金和一般企业用途，包括行政和研发费用。该协议包含标准的终止条款，并允许任何一方在特定条件下暂停或终止发行。
ZyVersa Therapeutics于2024年9月16日与A.G.P./Alliance Global Partners签署销售协议，建立一个高达1,397,396美元的市场出售（ATM）提供计划。根据协议，A.G.P.将担任销售代理，并获得出售股票毛收入的3%佣金。股票将在允许的市场价格下通过证劵法第415(a)(4)条款的协议方法出售。该发行是根据公司提交给美国证券交易委员会的有效S-3架构注册声明进行的。虽然没有最低发行金额的要求，但一旦达到最大发行金额，协议将自动终止。公司计划将净收益用于营运资金和一般企业用途，包括行政和研发费用。该协议包含标准的终止条款，并允许任何一方在特定条件下暂停或终止发行。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    vTv Therapeutics
    VTVT
    -- 22.7400
    Galmed Pharmaceuticals
    GLMD
    -- 2.5000
    CervoMed
    CRVO
    -- 9.050
    Alzamend Neuro
    ALZN
    -- 0.8949
    Verrica制药
    VRCA
    -- 0.651
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股持续上涨：哪些因素将主导后市？
    🎙️讨论 1. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 2. 近期中概股上涨的主要驱动力是政策预期还是资金面改善？ 3. 若涨势延续，你会更关注技术面突破还是基本面支撑？ 展开
    中国两会：会议前后股票价格走势的主要要点